Compare Immunovant Inc. Common Stock (IMVT) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs SpaceX — how do they compare? Immunovant Inc. Common Stock trades at $30.41 (market cap $6.25B), while SpaceX trades at $163.26 (market cap $2.18T). The key difference: SpaceX is far larger — about 348.8× Immunovant Inc. Common Stock's market cap, and SpaceX is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and SpaceX for 41 Days on average.
| IMVT | SPCX | |
|---|---|---|
Market Cap | $6.25B | $2.18T |
Volume | 1,755,411 | 68,508,567 |
Sector | Health | Industrials |
52-Week High | $44.96 | $202.09 |
52-Week Low | $17.03 | $108.27 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $5.35B | $2.12T |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
